Frankfurt - Delayed Quote EUR

Xvivo Perfusion AB (publ) (3XV.F)

27.66
+0.08
+(0.29%)
At close: May 9 at 8:05:26 AM GMT+2
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
854,981
822,415
597,542
415,292
258,386
Cost of Revenue
213,298
206,000
152,431
118,336
70,107
Gross Profit
641,683
616,415
445,111
296,956
188,279
Operating Expense
544,704
527,009
439,715
292,501
207,021
Operating Income
96,979
89,406
5,396
4,455
-18,742
Net Non Operating Interest Income Expense
27,299
78,931
80,441
1,029
19,471
Pretax Income
155,889
199,948
94,521
22,314
6,665
Tax Provision
18,891
27,766
2,701
3,887
-1,487
Net Income Common Stockholders
136,998
172,182
91,820
18,427
8,152
Diluted NI Available to Com Stockholders
136,998
172,182
91,820
18,427
8,152
Basic EPS
4.36
5.47
3.07
0.62
0.28
Diluted EPS
4.33
5.44
3.07
0.62
0.28
Basic Average Shares
31,499.47
31,499.47
29,935.15
29,525.95
28,845.69
Diluted Average Shares
31,687.77
31,650.11
29,935.15
29,525.95
28,936.08
Total Operating Income as Reported
95,926
88,353
4,187
6,409
-18,498
Total Expenses
758,002
733,009
592,146
410,837
277,128
Net Income from Continuing & Discontinued Operation
136,998
172,182
91,820
18,427
8,152
Normalized Income
137,683.48
172,852.80
92,790.97
18,644.46
8,184.55
Interest Income
--
17,155
8,850
2,123
0
Interest Expense
--
1,260
1,190
605
276
Net Interest Income
27,299
78,931
80,441
1,029
19,471
EBIT
208,781
201,208
95,711
22,919
6,941
EBITDA
208,781
288,924
172,061
65,086
39,198
Reconciled Cost of Revenue
213,298
206,000
152,431
118,336
70,107
Reconciled Depreciation
--
87,716
76,350
42,167
32,257
Net Income from Continuing Operation Net Minority Interest
136,998
172,182
91,820
18,427
8,152
Total Unusual Items Excluding Goodwill
-780
-780
-1,001
-262
-41
Total Unusual Items
-780
-780
-1,001
-262
-41
Normalized EBITDA
209,561
289,704
173,062
65,348
39,239
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-94.52
-109.20
-30.03
-44.54
-8.45
12/31/2021 - 7/22/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

8ZF.F Polarean Imaging plc
0.0005
-92.86%
 
A2P.F Synektik Spólka Akcyjna
53.65
-1.47%
 
NEOLA.ST Neola Medical AB (publ)
2.4400
+0.83%
 
PHIA.F Koninklijke Philips N.V.
21.40
+0.94%
 
LT3.F Axogen, Inc.
11.40
+1.79%
 
PHIAa.XC
 
EPIS-B.ST Episurf Medical AB (publ)
0.1110
+0.91%
 
CGHC Capital Group Holdings, Inc.
0.0002
0.00%
 
VIRO.CO ViroGates A/S
6.66
-1.19%
 
MHC.L MyHealthChecked PLC
13.50
0.00%